News & Updates
Showing Pharmacy articles
Showing
Ongoing treatment required in severe patchy hair loss
For patients with severe alopecia areata who achieved meaningful hair regrowth with 1-year course of baricitinib, subsequent discontinuation appears to reverse treatment gains, highlighting the need for ongoing therapy.
Chemo plus atezolizumab improves survival while preserving life quality in advanced EC
Treatment with carboplatin-paclitaxel (CP) plus atezolizumab results in better quality-adjusted survival in patients with advanced or recurrent endometrial cancer (EC) as compared with CP alone, according to a post hoc analysis of the AtTEnd/ENGOT-EN7 trial.
OCS use improves short-term outcomes in acute preschool wheeze
In a systematic review and individual participant data (IPD) meta-analysis, the use of oral corticosteroids (OCS) improves short-term outcomes in children aged 12–71 months with acute preschool wheeze, more so among children with previous wheeze or asthma and those with moderate-to-severe acute wheeze.
Tadalafil helps recover erectile function in young men with ED
Nearly one in two young men with primary psychogenic erectile dysfunction (ED) treated with tadalafil 5 mg once daily achieve spontaneous medication-free erectile function (EF) at 3 months, as shown in a study. Younger patients tend to have a higher chance of recovery after drug discontinuation.
Navitoclax–ruxolitinib combo doubles spleen response rates in myelofibrosis
In untreated myelofibrosis, using navitoclax in combination with ruxolitinib appears to result in a twofold increase in the number of patients experiencing spleen volume shrinkage, regardless of prognosis, according to updated data from the phase III TRANSFORM-1 trial.
Adjunctive brexpiprazole benefits seen in Asian adults with MDD in real-world
Up to 3 months of treatment with adjunctive brexpiprazole helps with symptom severity in Asian adults with major depressive disorder (MDD) and inadequate response to antidepressants in a real-life clinical setting in Singapore.
